TapImmune Completes Transfer of IND From The Mayo Clinic

Significant Milestone Marks The Next Major Step in Beginning Phase 2 Trials in Cancer Using The Folate Receptor Alpha Peptide Vaccine Technology

Aug 18, 2015, 08:30 ET from TapImmune, Inc.

SEATTLE, Wash., Aug. 18, 2015 /PRNewswire/ -- TapImmune, Inc. (OTCQB: TPIV),  a clinical stage immunotherapy company, specializing in the development of innovative technologies for the treatment of metastatic cancer, announced today the successful conveyance of the Mayo Clinic IND (Investigational New Drug Application)  to TapImmune as part of the recently completed licensing agreement. The transfer marks a critical step in reaching the Company's major milestone of initiating TapImmune's sponsored Phase 2 trials in patients with triple-negative breast cancer or ovarian cancer.

TapImmune recently announced positive Phase 1 clinical data from the Folate Receptor Alpha vaccine trial in patients with breast or ovarian cancer. This trial demonstrated the experimental therapy was safe, well-tolerated and provided a robust immune response in 20 out of 21 evaluable patients. Data from the Phase 1 trials were published in abstract form during the 2015 ASCO meeting.  http://meetinglibrary.asco.org/content/148110-156.  

The Company plans to utilize funds received from the recently exercised warrants from a previous financing, to sponsor Proof of Concept Phase 2 clinical studies in patients with triple negative breast or  ovarian cancer under its own IND. Dr. Glynn Wilson, Chairman & CEO of TapImmune, stated "We believe the transfer of the IND to the Company represents the beginning of a new era for TapImmune. We now have the resources and regulatory pathway to chart our own course in developing a promising cancer vaccine to meet unmet medical needs."

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details. 

Forward-Looking Statement Disclaimer 

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

Contacts:

TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1-866-359-7541

PCG Advisory
Kirin M. Smith
Chief Operating Officer
+1-646-863-6519

Sean Leous
Chief Communications Officer
+1-646-863-8998
www.pcgadvisory.com

J. Streicher Capital, LLC
Robert Giordano
+1-917-327-3938

SOURCE TapImmune, Inc.



RELATED LINKS

http://www.tapimmune.com